Champions Oncology, Inc. provided revenue guidance for the fiscal year 2023. For the period, the company expecting its total revenue growth for fiscal 2023 to be in the 10% to 15% range, down from the approximate 20% range provided at the beginning of the year.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.77 USD | +5.30% | +5.53% | -15.12% |
03-15 | Tranche Update on Champions Oncology, Inc.'s Equity Buyback Plan announced on April 5, 2023. | CI |
03-13 | Craig-Hallum Downgrades Champions Oncology to Hold From Buy | MT |
1st Jan change | Capi. | |
---|---|---|
-15.12% | 61.58M | |
+48.64% | 54.63B | |
-6.44% | 39.92B | |
+37.07% | 38.82B | |
+14.28% | 26.86B | |
-11.17% | 26.22B | |
-21.40% | 18.78B | |
+25.64% | 12.21B | |
+0.96% | 12.16B | |
+27.04% | 11.94B |
- Stock Market
- Equities
- CSBR Stock
- News Champions Oncology, Inc.
- Champions Oncology, Inc. Provides Revenue Guidance for the Fiscal Year 2023